9 research outputs found
La Grange Comprehensive Plan 2018 - 2038
In the Fall of 2017, the City of La Grange and Texas Target Communities partnered to create
a task force to represent the community. The task force was integral to the planning process,
contributing the thoughts, desires, and opinions of community members—as well as their
enthusiasm about La Grange’s future. This fifteen-month planning process ended in August
2018. The result of this collaboration is the La Grange Comprehensive Plan, which is the
official policy guide for the community’s growth over the next twenty years.La Grange Comprehensive Plan 2018 - 2038 provides a guide for the future growth of the City.
This document was developed by Texas Target Communities in partnership with the City of
La Grange.Texas Target Communitie
Rockport Comprehensive Plan
This document was developed and prepared by Texas Target Communities (TxTC) at Texas A&M University
in partnership with the City of Rockport, Texas Sea Grant, Texas A&M University - Corpus Christi,
Texas A&M University - School of Law and Texas Tech University.Founded in 1871, the City of Rockport aims to continue growing economically and sustainably. Rockport is a resilient community dedicated to sustainable growth and attracting businesses to the area. Rockport is a charming town that offers a close-knit community feel and is a popular tourist destination for marine recreation, fairs, and exhibitions throughout the year. The Comprehensive Plan 2020-2040 is designed to guide the city of Rockport for its future growth. The guiding principles for this planning process were Rockport's vision statement and its corresponding goals, which were crafted by the task force. The goals focus on factors of growth and development including public participation, development considerations, transportation, community facilities, economic development, parks, and housing and social vulnerability
Legal Education in the Blockchain Revolution
The legal profession is one of the most disrupted sectors of the consulting industry today. The rise of Legal Technology, artificial intelligence, big data, machine learning, and, most importantly, blockchain technology is changing the practice of law. The sharing economy and platform companies challenge many of the traditional assumptions, doctrines, and concepts of law and governance--requiring litigators, judges, and regulators to adapt. Lawyers need to be equipped with the necessary skill sets to operate effectively in the new world of disruptive innovation in law. A more creative and innovative approach to educating lawyers for the twenty-first century is needed
Nolanville Comprehensive Plan 2021-2041
Nearly five years after the completion of the 2015 Comprehensive Plan, TxTC partnered with the City of Nolanville again in 2019 with the ENDEAVR project. ENDEAVR (Envisioning the Neo-traditional Development by Embracing the Autonomous Vehicles Realm)— is an ambitious project to re-envision ”smart” city solutions in small towns with students from a wide range of university degree programs in urban planning, landscape architecture, visualization, computer science, and civil, electrical and mechanical engineering. ENDEAVR launched in 2018 with a $300,000 grant from the Keck Foundation, which supports projects that promote inventive educational approaches.
The City of Nolanville sought to explore “smart” city solutions to make efficient and prudent improvements to traffic flow, public safety, optimize utility systems, high-bandwidth digital networks, and foster autonomous vehicles. Additionally, TxTC included these “smart” city solutions to update its 2015 comprehensive plan. The new 2020 comprehensive plan embeds “smart” city solutions into its priorities and capital improvement projects to foster diversity and continue to make Nolanville “A Great Place to Live”
Recommended from our members
Risk of COVID-19 after natural infection or vaccinationResearch in context
Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health
Risk of COVID-19 after natural infection or vaccinationResearch in context
Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health